申联生物(688098) - 2021 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders decreased by 39.77% to CNY 28,383,703.58 year-on-year[6] - Operating revenue declined by 15.84% to CNY 82,854,949.85 compared to the same period last year[6] - Basic earnings per share decreased by 41.67% to CNY 0.07[6] - Weighted average return on equity decreased by 1.60 percentage points to 2.01%[6] - Total revenue decreased by 15.84% year-over-year, while operating profit fell by 37.54% to ¥32,498,668.50[15] - Net profit dropped by 40.62% to ¥27,985,577.40, attributed to increased management and sales expenses[14] - Net profit for Q1 2021 was ¥27,985,577.40, down 40.5% from ¥47,128,914.92 in Q1 2020[32] - The net profit for Q1 2021 was CNY 28,797,872.09, a decrease of 38.8% compared to CNY 47,128,914.92 in Q1 2020[35] - The total comprehensive income for Q1 2021 was CNY 28,797,872.09, down from CNY 47,128,914.92 in Q1 2020, indicating a decline of 38.8%[35] Cash Flow - Net cash flow from operating activities was negative at CNY -43,438,746.69, a decrease of 241.91% compared to the previous year[6] - Cash flow from operating activities showed a net outflow of ¥43,438,746.69, a decline of 241.91% compared to the same period last year[16] - Cash flow from operating activities showed a net outflow of CNY 43,438,746.69, worsening from a net outflow of CNY 12,704,566.96 in Q1 2020[37] - The total cash outflow from operating activities was CNY 84,878,343.73, compared to CNY 56,169,425.08 in Q1 2020, representing an increase of 50.9%[37] - The total cash outflow from operating activities was $83.95 million, compared to $56.17 million in the previous year, indicating increased operational costs[41] Assets and Liabilities - Total assets increased by 1.10% to CNY 1,531,087,711.10 compared to the end of the previous year[6] - Total current assets as of March 31, 2021, amounted to ¥773,267,482.50, a decrease of 2.3% from ¥793,859,102.41 on December 31, 2020[22] - Total non-current assets reached ¥757,820,228.60, an increase of 5.2% from ¥720,610,345.32[23] - Total liabilities decreased to ¥102,428,950.10 from ¥118,203,564.13, a reduction of 13.4%[24] - Total liabilities as of Q1 2021 were ¥102,349,850.10, a decrease from ¥118,124,750.68 in the previous year[28] - The company's equity attributable to shareholders increased to ¥1,429,203,891.03 from ¥1,396,412,887.45, marking a rise of 2.3%[25] Research and Development - R&D investment as a percentage of operating revenue increased by 8.42 percentage points to 17.06%[6] - Development expenses surged by 489.59% to ¥11,111,256.01, as the company’s vaccine research project entered the capitalization phase[12] - The company’s R&D expenses decreased by 30.03% to ¥4,904,462.76, as more costs were capitalized due to the vaccine project[13] - The company plans to consolidate its vaccine production lines in Lanzhou to strengthen biosecurity measures[19] Shareholder Information - The total number of shareholders reached 10,121 by the end of the reporting period[9] - The largest shareholder, Yang Yufang, holds 21.98% of the shares[9] - UNITED BIOMEDICAL, INC. holds 16.16% of the shares but has some shares frozen[9] Investment Activities - Total cash inflow from investment activities was CNY 958,297,810.75, compared to CNY 742,125,494.90 in Q1 2020, marking an increase of 29.2%[38] - The company reported a significant increase in cash inflow from investment activities, primarily due to cash recovered from investments amounting to CNY 954,700,000.00, up from CNY 737,900,000.00 in Q1 2020[38] - The net cash flow from investment activities was $12.89 million, a turnaround from -$62.33 million in the same quarter last year, showing improved investment performance[41] Operational Costs - Total operating costs increased to ¥52,634,829.93, up 4.9% from ¥50,178,398.65 in the same period last year[31] - Management expenses rose to ¥18,000,886.57, an increase of 30.5% compared to ¥13,759,760.59 in Q1 2020[32] - The company paid $32.19 million in employee compensation, an increase from $24.59 million in the same quarter last year, reflecting growth in workforce expenses[41]